Bausch + Lomb (BLCO) Expected to Announce Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is expected to be issuing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Bausch + Lomb to post earnings of $0.16 per share and revenue of $1.2760 billion for the quarter. Bausch + Lomb has set its FY 2025 guidance at EPS.Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 8:00 AM ET.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the firm earned $0.13 earnings per share. The business’s revenue was up 5.1% on a year-over-year basis. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Stock Performance

Shares of NYSE:BLCO opened at $15.66 on Wednesday. The business has a fifty day moving average of $14.86 and a 200-day moving average of $13.37. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.55. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $20.94. The firm has a market cap of $5.55 billion, a PE ratio of -20.08, a price-to-earnings-growth ratio of 1.72 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Morgan Stanley raised their price objective on shares of Bausch + Lomb from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Citigroup reissued a “neutral” rating on shares of Bausch + Lomb in a report on Tuesday, October 7th. Wells Fargo & Company upped their price objective on Bausch + Lomb from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bausch + Lomb in a research report on Wednesday, October 8th. Finally, HC Wainwright boosted their target price on Bausch + Lomb from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $15.70.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Glenview Capital Management LLC grew its stake in shares of Bausch + Lomb by 210.8% during the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after purchasing an additional 1,053,855 shares during the period. Goldman Sachs Group Inc. lifted its stake in Bausch + Lomb by 428.7% in the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after buying an additional 242,993 shares during the period. PDT Partners LLC boosted its holdings in Bausch + Lomb by 182.3% during the second quarter. PDT Partners LLC now owns 172,209 shares of the company’s stock worth $2,240,000 after buying an additional 111,206 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Bausch + Lomb during the second quarter worth about $592,000. Finally, Jump Financial LLC acquired a new position in shares of Bausch + Lomb during the 2nd quarter worth about $313,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.